| |
| |
|
| Insider
Information: |
Hoberman Kenneth |
| Relationship: |
Director |
| City: |
New York |
| State: |
NY |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
3 |
|
| Direct
Shares |
297,825 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$4,169,328 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
297,825 |
|
|
| Total
Value |
$4,169,328 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
5
|
|
Stock
price went up :
|
0
|
5
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
5.0
|
| Percentage
Gain/Loss : |
0.0%
|
 402.2%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Stemline Therapeutics Inc |
STML |
Chief Operating Officer |
2020-06-10 |
0 |
|
0 |
Premium* |
|
|
TG Therapeutics Inc |
TGTX |
Director |
2023-09-28 |
242,685 |
|
0 |
Premium* |
|
|
Nuvectis Pharma, Inc. |
NVCT |
Director |
2022-05-12 |
55,140 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
71 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 3
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| STML |
Stemline Therapeutics Inc |
Chief Operating OfficerOfficer |
• – – |
2013-03-25 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
19,288 |
|
- |
|
| TGTX |
TG Therapeutics Inc |
Director |
– • – |
2014-12-15 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
64,223 |
|
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Director |
– • – |
2022-02-08 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
49,140 |
|
- |
|
| STML |
Stemline Therapeutics Inc |
Chief Operating Officer |
• – – |
2017-12-18 |
4 |
S |
$14.75 |
$590 |
D/D |
(40) |
398,832 |
0 |
- |
|
| STML |
Stemline Therapeutics Inc |
Chief Operating Officer |
• – – |
2019-03-12 |
4 |
S |
$11.04 |
$10,830 |
D/D |
(981) |
755,696 |
0 |
- |
|
| STML |
Stemline Therapeutics Inc |
Chief Operating Officer |
• – – |
2016-02-17 |
4 |
S |
$4.54 |
$6,824 |
D/D |
(1,503) |
211,059 |
0 |
- |
|
| STML |
Stemline Therapeutics Inc |
Chief Operating Officer |
• – – |
2017-02-16 |
4 |
S |
$6.42 |
$9,681 |
D/D |
(1,508) |
287,682 |
0 |
- |
|
| STML |
Stemline Therapeutics Inc |
Chief Operating Officer |
• – – |
2015-02-18 |
4 |
S |
$14.02 |
$22,334 |
D/D |
(1,593) |
87,942 |
0 |
- |
|
| STML |
Stemline Therapeutics Inc |
Chief Operating Officer |
• – – |
2018-02-15 |
4 |
S |
$15.67 |
$29,005 |
D/D |
(1,851) |
382,941 |
0 |
- |
|
| STML |
Stemline Therapeutics Inc |
Chief Operating Officer |
• – – |
2014-09-02 |
4 |
B |
$10.99 |
$21,975 |
D/D |
2,000 |
89,535 |
2.74 |
- |
|
| STML |
Stemline Therapeutics Inc |
Chief Operating Officer |
• – – |
2019-12-27 |
4 |
S |
$10.48 |
$21,191 |
D/D |
(2,022) |
636,452 |
0 |
- |
|
| STML |
Stemline Therapeutics Inc |
Chief Operating Officer |
• – – |
2017-03-07 |
4 |
S |
$8.16 |
$19,111 |
D/D |
(2,342) |
277,674 |
0 |
- |
|
| STML |
Stemline Therapeutics Inc |
Chief Operating Officer |
• – – |
2016-03-08 |
4 |
S |
$5.34 |
$12,880 |
D/D |
(2,412) |
297,392 |
0 |
- |
|
| STML |
Stemline Therapeutics Inc |
Chief Operating Officer |
• – – |
2019-03-07 |
4 |
S |
$11.36 |
$34,023 |
D/D |
(2,995) |
781,778 |
0 |
- |
|
| STML |
Stemline Therapeutics Inc |
Chief Operating Officer |
• – – |
2018-03-07 |
4 |
S |
$16.55 |
$50,097 |
D/D |
(3,027) |
369,278 |
0 |
- |
|
| STML |
Stemline Therapeutics Inc |
Chief Operating Officer |
• – – |
2013-11-26 |
4 |
S |
$21.27 |
$66,873 |
D/D |
(3,144) |
69,238 |
0 |
- |
|
| STML |
Stemline Therapeutics Inc |
Chief Operating Officer |
• – – |
2017-02-27 |
4 |
S |
$6.97 |
$27,880 |
D/D |
(4,000) |
283,682 |
0 |
- |
|
| STML |
Stemline Therapeutics Inc |
Chief Operating Officer |
• – – |
2017-02-28 |
4 |
S |
$7.01 |
$28,229 |
D/D |
(4,027) |
279,655 |
0 |
- |
|
| STML |
Stemline Therapeutics Inc |
Chief Operating Officer |
• – – |
2019-12-23 |
4 |
S |
$10.58 |
$45,695 |
D/D |
(4,319) |
678,445 |
0 |
- |
|
| TGTX |
TG Therapeutics Inc |
Director |
– • – |
2015-06-04 |
4 |
A |
$0.00 |
$0 |
D/D |
4,667 |
74,446 |
0 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Director |
– • – |
2022-05-12 |
4 |
B |
$17.40 |
$104,400 |
D/D |
6,000 |
55,140 |
2.39 |
- |
|
| STML |
Stemline Therapeutics Inc |
Chief Operating Officer |
• – – |
2013-11-26 |
4 |
OE |
$1.11 |
$7,733 |
D/D |
6,967 |
72,382 |
0 |
- |
|
| STML |
Stemline Therapeutics Inc |
Chief Operating Officer |
• – – |
2019-06-24 |
4 |
S |
$15.49 |
$141,067 |
D/D |
(9,107) |
720,772 |
0 |
- |
|
| STML |
Stemline Therapeutics Inc |
Chief Operating Officer |
• – – |
2017-01-10 |
4 |
S |
$13.82 |
$125,900 |
D/D |
(9,110) |
289,190 |
0 |
- |
|
| STML |
Stemline Therapeutics Inc |
Chief Operating Officer |
• – – |
2020-03-09 |
4 |
S |
$5.08 |
$48,194 |
D/D |
(9,487) |
788,468 |
0 |
% |
|
71 Records found
|
|
Page 1 of 3 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
